超早期重组组织型纤溶酶原激活物溶栓治疗脑梗死的临床研究

目的 探讨重组组织型纤溶酶原激活物（rt—PA）静脉溶栓治疗超早期脑梗死的安全性与有效性。方法 按入选标准筛选合适患者21例进行溶栓，以相同时期非溶栓治疗的具有相同条件的患者20例为对照组，在溶栓前及溶栓后24h、21d按欧洲脑卒中神经功能缺损评分标准（ESS）进行评定，3个月时按Barthel指数进行评定。结果 溶栓组疗效优于对照组（P〈0．05）。溶栓组脑出血发生1例，预后仍然良好。两组患者均无死亡病例。结论 rt—PA静脉溶栓治疗超早期急性脑梗死安全、有效。

Effect of Recombinant Tissue-type Plasminogen Activator on Hyperacute Cerebral Infarction

ObjectiveTo study the efficacy and safety of intravenous recombinant tissue-type plasminogen activator (rt-PA) on hyperacute cerebral infarction. Methods41 patients with the supra-early acute cerebral infarction were divided into two groups: thrombolytic group (n=21) and control group (n=20). They were evaluated with European Stroke Scale (ESS) and Barthel Index before and 24 h, 21 d, 90 d after treatment. ResultsThe scores of the thrombolytic group showed more efficacious than that of the control groups (P<0.05). One patient suffered from cerebral hemorrhage in thrombolytic group, however his prognosis was good. There was no death in both groups. ConclusionThrombolytic therapy with rt-PA in the hyperacute cerebral infarction shows positive effect and safety.